January 31, 2026 a 06:00 pm
GILD: Fundamental Ratio Analysis - Gilead Sciences, Inc.
Gilead Sciences, Inc. stands out as a prominent player in the biopharmaceutical sector with a broad portfolio addressing unmet medical needs. With a focus on HIV/AIDS, liver diseases, and other serious conditions, the company has remained resilient in evolving healthcare landscapes. A solid historical performance paired with strategic collaborations offers promising prospects for sustained growth.
Fundamental Rating
The fundamental analysis of Gilead Sciences indicates robust financial health and strategic positioning, yielding a strong overall score. The diversified product range and partnerships enhance its market position.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return On Equity | 5 | |
| Return On Assets | 5 | |
| Debt To Equity | 1 | |
| Price To Earnings | 3 | |
| Price To Book | 1 |
Historical Rating
Tracking historical ratings reveals consistent fundamental strengths, indicating Gilead's enduring market position and fiscal resilience.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-01-30 | 4 | 5 | 5 | 5 | 1 | 3 | 1 |
| Historical | 0 | 5 | 5 | 5 | 1 | 3 | 1 |
Analyst Price Targets
Analysts present a positive outlook, with a high target of $155 and a consensus to buy, reinforcing confidence in future performance.
| High | Low | Median | Consensus |
|---|---|---|---|
| $155 | $105 | $140 | Buy |
Analyst Sentiment
The analyst recommendations lean heavily towards a 'Buy,' reflecting strong confidence in Gilead's trajectory among financial experts.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 37 | |
| Hold | 19 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Gilead Sciences, Inc. presents a compelling investment opportunity with a strong product portfolio and strategic alliances supplementing its broad market reach. While the debt-to-equity ratio remains a consideration, the overall financial position and expert backing provide a positive outlook. Fluctuations in stock price are expected, yet the long-term growth potential remains intact, driven by innovation and market demand. Investors may find the current valuations attractive as part of a diversified investment strategy.